Investment Thesis
SELLAS Life Sciences faces severe operational distress with revenue collapsed to $79K (-100% YoY) and substantial operating losses of $9.3M, indicating critical pipeline or commercialization failures typical of troubled biotech firms. While the company maintains a strong balance sheet with $107M cash and zero debt, operating cash burn of $8.8M annually combined with minimal revenue generation creates an unsustainable business model requiring significant clinical or commercial breakthroughs to avoid extended dilution.
Strengths
- Fortress balance sheet with $107.1M cash and zero long-term debt
- Exceptional liquidity position (17.22x current ratio) providing 12+ years of cash runway at current burn rate
- Minimal capital expenditure requirements ($6K) indicating lean operations
Risks
- Near-total revenue collapse (-100% YoY to $79K) suggesting failed commercialization or major pipeline setbacks
- Sustained operating cash burn of $8.8M annually with negative free cash flow
- Complete absence of insider buying activity despite potential deep valuation, indicating management lacks confidence in recovery
- As pharmaceutical company, revenue collapse suggests failed clinical trials or severe regulatory/market challenges
Key Metrics to Watch
- Quarterly revenue trend and pipeline advancement announcements
- Operating cash burn rate trajectory
- Clinical trial progress and FDA communications
- Cash runway sufficiency given revised operating plan
Financial Metrics
Revenue
79.0K
Net Income
-8.4M
EPS (Diluted)
$-0.05
Free Cash Flow
-8.9M
Total Assets
114.2M
Cash
107.1M
Profitability Ratios
Gross Margin
1,224.1%
Operating Margin
-11,711.4%
Net Margin
-10,641.8%
ROE
-7.8%
ROA
-7.4%
FCF Margin
-11,205.1%
Balance Sheet & Liquidity
Current Ratio
17.22x
Quick Ratio
17.22x
Debt/Equity
0.00x
Debt/Assets
5.9%
Interest Coverage
-12.09x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T09:11:52.036198 |
Data as of: 2026-03-31 |
Powered by Claude AI